Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1971532
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
Telomir Pharma filed an 8-K on 12/23/24 for 'Other Events' - details TBD.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on December 23, 2024, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Telomir Pharmaceuticals, Inc., but the lack of detail requires further investigation to understand its implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, creating uncertainty about the nature and impact of the reported event.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- December 23, 2024 (date) — Date of Report
- Florida (location) — State of Incorporation
- Miami (location) — Principal Executive Offices City
FAQ
What specific event(s) are being reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond the general categorization.
Are there any financial implications or dollar amounts associated with the 'Other Events' reported?
The provided filing excerpt does not mention any specific dollar amounts related to the 'Other Events'.
Does the filing provide any context or explanation for why these events are being reported on December 23, 2024?
The filing states December 23, 2024, as the date of the earliest event reported, but offers no further explanation for the timing.
What is the principal business of Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are Telomir Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 15.4 · Accepted 2024-12-23 07:00:34
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-051191.txt ( ) — 208KB
- telo-20241223.xsd (EX-101.SCH) — 3KB
- telo-20241223_lab.xml (EX-101.LAB) — 33KB
- telo-20241223_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACUTICALS, INC. Dated: December 23, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer